Incyte Corp
DUS:ICY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Incyte Corp
DUS:ICY
|
US |
|
Indofood CBP Sukses Makmur Tbk PT
F:48I
|
ID |
|
Prospector Metals Corp
XTSX:PPP
|
CA |
|
Fluence Corporation Ltd
ASX:FLC
|
US |
Intrinsic Value
Is ICY undervalued or overvalued?
See the intrinsic value estimate for 
Incyte Corp and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
ICY looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with ICY’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Incyte Does
Incyte Corp is a biopharmaceutical company that discovers, develops, and sells prescription medicines, mainly for cancer and immune-related diseases. Its best-known products include treatments used by specialists in oncology and dermatology, where doctors prescribe the drugs to patients with conditions such as blood cancers, graft-versus-host disease, and inflammatory skin disorders.
- Headquarters
- United States of America US
- Employees
- 2 844
- IPO date
- Dec 6, 1993
Incyte has no economic moat
Incyte’s medicines face other treatments that doctors and patients can choose instead, and customers generally are not locked into using the company’s products. Patents can hold off copies for a time, but they do not protect the business indefinitely as other drugs compete for the same patients.
Read the full moat analysis
Revenue & Expenses Breakdown
Incyte Corp
Earnings Waterfall
Incyte Corp
The intrinsic value for Incyte Corp (ICY) under the Base Case is hidden EUR.
Compared with the current market price of 102.3 EUR, the stock appears hidden.